Christopher G Chapman1, Irving Waxman2. 1. Center for Endoscopic Research and Therapeutics (CERT), The University of Chicago Medicine and Biological Sciences, 5700 S Maryland Ave. MC 8043, Chicago, IL, 60637, USA. 2. Center for Endoscopic Research and Therapeutics (CERT), The University of Chicago Medicine and Biological Sciences, 5700 S Maryland Ave. MC 8043, Chicago, IL, 60637, USA. Christopher.Chapman@uchospitals.edu.
Abstract
PURPOSE OF REVIEW: Although liquid biopsies hold significant promise in the management of patients with cancer, peripheral blood analyses remain dependent on the degree of tumor burden with prohibitively low yields until the cancer is widely metastatic. Multiple lines of evidence support a dynamic, spatiotemporal localization of circulating tumor cells (CTCs) supporting specific targeting of vascular compartments, such as the portal vein. This review discusses the literature evaluating the possibility of portal venous blood as a new, potentially higher yield liquid biopsy and the current devices and techniques for endoscopic ultrasound (EUS)-guided portal venous sampling for CTC detection. RECENT FINDINGS: Two recent studies in pancreatic cancer have demonstrated that portal venous blood can be safely sampled via EUS and consistently yields significantly higher CTC counts compared with matched peripheral blood. EUS-acquired samples can be used for molecular testing, clinical prognostication, and drug sensitivity analyses. Portal venous CTCs are identified in higher quantity relative to peripheral blood and can be safely obtained via EUS. Further studies are required to demonstrate the clinical utility of EUS-guided portal venous tumor material enrichment and analysis; however, obtaining EUS-guided "liquid biopsies" appears to merit significant consideration for procedural adoption.
PURPOSE OF REVIEW: Although liquid biopsies hold significant promise in the management of patients with cancer, peripheral blood analyses remain dependent on the degree of tumor burden with prohibitively low yields until the cancer is widely metastatic. Multiple lines of evidence support a dynamic, spatiotemporal localization of circulating tumor cells (CTCs) supporting specific targeting of vascular compartments, such as the portal vein. This review discusses the literature evaluating the possibility of portal venous blood as a new, potentially higher yield liquid biopsy and the current devices and techniques for endoscopic ultrasound (EUS)-guided portal venous sampling for CTC detection. RECENT FINDINGS: Two recent studies in pancreatic cancer have demonstrated that portal venous blood can be safely sampled via EUS and consistently yields significantly higher CTC counts compared with matched peripheral blood. EUS-acquired samples can be used for molecular testing, clinical prognostication, and drug sensitivity analyses. Portal venous CTCs are identified in higher quantity relative to peripheral blood and can be safely obtained via EUS. Further studies are required to demonstrate the clinical utility of EUS-guided portal venous tumor material enrichment and analysis; however, obtaining EUS-guided "liquid biopsies" appears to merit significant consideration for procedural adoption.
Authors: Sabine Riethdorf; Herbert Fritsche; Volkmar Müller; Thomas Rau; Christian Schindlbeck; Brigitte Rack; Wolfgang Janni; Cornelia Coith; Katrin Beck; Fritz Jänicke; Summer Jackson; Terrie Gornet; Massimo Cristofanilli; Klaus Pantel Journal: Clin Cancer Res Date: 2007-02-01 Impact factor: 12.531
Authors: Long R Jiao; Christos Apostolopoulos; Jimmy Jacob; Richard Szydlo; Natalia Johnson; Nicole Tsim; Nagy A Habib; R Charles Coombes; Justin Stebbing Journal: J Clin Oncol Date: 2009-11-02 Impact factor: 44.544
Authors: Massimiliano Bissolati; Maria Teresa Sandri; Giovanni Burtulo; Laura Zorzino; Gianpaolo Balzano; Marco Braga Journal: Tumour Biol Date: 2014-10-16
Authors: M J Slade; R Payne; S Riethdorf; B Ward; S A A Zaidi; J Stebbing; C Palmieri; H D Sinnett; E Kulinskaya; T Pitfield; R T McCormack; K Pantel; R C Coombes Journal: Br J Cancer Date: 2008-11-25 Impact factor: 7.640